The list below shows The Lymphoma Group's current clinical trials open/due to open for recruitment for Diffuse large B-cell lymphoma patients.
If you would like to know how to access our trials, please see how to contact us.
- GEN3013 - Phase 1/2 study using antibody GEN3013 to target CD20- expressing cells in patients with B cell non Hodgkin lymphoma
Suitable for patients with B cell non-Hodgkin lymphoma which has come back after previous treatment - JCAR017 - Phase 2 study determining efficacy and safety of JCAR017
Suitable for patients with lymphoma which has come back after previous treatment
- GO29781 - A phase 1/1b trial testing mosunetuzumab, on its own or with atezolizumab
Suitable for patients with lymphoma which has come back after previous treatment - GCT3013-02 - A phase 1b/2 trial of a targeted treatment, epcoritamab, in combination with different chemotherapy regimens, in people with B-cell non-Hodgkin lymphoma.
- LOTIS-3 - A phase 1/2 trial of loncastuximab tesirine and ibrutinib in people with relapsed or refractory diffuse large B-cell lymphoma or mantle cell lymphoma.
With special thanks to the following: